<DOC>
	<DOCNO>NCT01697618</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacokinetics , pharmacodynamics safety biphasic insulin aspart 30 subject type 2 diabetes .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics Safety Biphasic Insulin Aspart 30 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes least 12 month Treated combination soluble/protracted human insulin ratio 30/70 twicedaily regimen least 6 month BMI ( body mass index ) 39 kg/m^2 HbA1c ( glycosylated haemoglobin ) 12 %</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>